009300.KQ Sam-A Pharm. Co. Ltd
- Market cap
- KRW 83.2B
- P/E
- -
- P/B
- 0.36x
- ROE
- 5.7%
- Dividend yield
- 5.87%
- Fundamental score
- 2.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 009300.KQ undervalued?
Graham numberThe Graham number of Sam-A Pharm. Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sam-A Pharm. Co. Ltd fundamental analysis
13 of 22 checks passedROE 0/2
Low return on equity (5.7%), below 10%.
ROA 1/1
Return on assets (5.3%) is above the industry median (3.4%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-41.4%) is not above the 5-year average (153.4% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-41.4%) is below the industry median (6.6%).
Revenue Growth 0/2
Revenue shrank 1.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (1.1%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.4x) is below the industry median (0.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 2/2
Dividend yield (5.9%) is in the top 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 37.7%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Sam-A Pharm. Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sam-A Pharm. Co. Ltd
Sam-A Pharm. Co., Ltd operates as a pharmaceutical company in South Korea. The company offers a range of pharmaceutical products in the areas of respiratory, anti-biotics, anti-virals, anti-histamines, anti-fungals, dermatology, pain/inflammation, gastrointestinal, cardiovascular, metabolism, urological, and steroids, as well as psychotropic agents; and OTC products in the areas of respiratory, ant-analgesics, gastro-intestinal, topical, oral, and anti-histamines. It also pr…
Full company profileSam-A Pharm. Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sam-A Pharm. Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 65.9B | 61.8B | 66.9B | 71.6B | 53.7B | 54.7B | 81.7B | 97.2B | 95.6B | 77.8B | 72.8B |
| Gross Profit | 40.5B | 38.3B | 40.8B | 43.7B | 32.4B | 32.7B | 50.2B | 61.6B | 60.8B | 46.4B | 41.3B |
| Operating Income | 9.58B | 7.53B | 9.36B | 10.4B | 3.93B | 6.05B | 18.3B | 23.5B | 24.5B | 11.0B | 7.90B |
| EBITDA | - | - | - | - | - | - | 21.7B | 32.6B | 34.1B | 21.3B | 12.9B |
| Net Income | 9.87B | 5.80B | 8.80B | 10.2B | 124M | 3.39B | 11.9B | 21.4B | 22.1B | 12.9B | 13.2B |
| EPS | 1,617 | 951 | 1,442 | 1,671 | 20 | 556 | 1,952 | 3,502 | 3,618 | 2,120 | 2,157 |
| Balance Sheet | |||||||||||
| Total Assets | 162B | 168B | 174B | 191B | 182B | 189B | 203B | 231B | 249B | 247B | 250B |
| Total Liabilities | 13.4B | 11.9B | 12.8B | 22.6B | 15.8B | 17.1B | 22.6B | 30.8B | 28.8B | 18.9B | 20.1B |
| Shareholders' Equity | 149B | 156B | 161B | 168B | 166B | 172B | 181B | 200B | 220B | 228B | 230B |
| Cash & Short-term Investments | 37.8B | 45.4B | 44.0B | 49.5B | 63.9B | 53.0B | 77.4B | 71.4B | 69.0B | 6.58B | 19.6B |
| Total Debt | - | - | - | 6.73B | 5.42B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 10.5B | 5.10B | 12.8B | 13.2B | 9.41B | 12.9B | 19.6B | 20.8B | 25.2B | 10.7B | 26.8B |
| Capital Expenditure | 1.16B | 3.68B | 2.40B | 492M | 680M | 275M | 239M | 3.82B | 6.51B | 1.78B | 2.35B |
| Free Cash Flow | - | - | - | - | 8.73B | 12.7B | 19.4B | 16.9B | 18.7B | 8.94B | 24.4B |
| Ratios | |||||||||||
| ROE | 6.6% | 3.7% | 5.5% | 6.1% | 0.1% | 2.0% | 6.6% | 10.7% | 10.0% | 5.7% | 5.7% |
| ROA | 6.1% | 3.5% | 5.1% | 5.3% | 0.1% | 1.8% | 5.9% | 9.2% | 8.9% | 5.2% | 5.3% |
| Net Profit Margin | 15.0% | 9.4% | 13.1% | 14.2% | 0.2% | 6.2% | 14.6% | 22.0% | 23.1% | 16.6% | 18.1% |
| Debt to Equity | - | - | - | 0.04x | 0.03x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sam-A Pharm. Co. Ltd dividends
- Dividend yield
- 5.87%
- Forward dividend
- -
- Payout ratio
- 37.7%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 4.88B | 800 | 37.7% |
| 2024 | KRW 4.58B | 750 | 20.7% |
| 2023 | KRW 2.44B | 400 | 11.4% |
| 2022 | KRW 1.53B | 250 | 12.8% |
| 2021 | KRW 1.83B | 300 | 54.0% |
| 2020 | KRW 1.83B | 300 | 1,478.4% |
| 2019 | KRW 1.53B | 250 | 15.0% |
| 2018 | KRW 1.53B | 250 | 17.3% |
| 2017 | KRW 1.53B | 250 | 26.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1119:1097 on Dec 29, 2008.
Who owns Sam-A Pharm. Co. Ltd
- Insiders 65.58%
- Institutions 0.00%
- Public & others 34.42%
- Shares outstanding 6.10M
- Free float 1.93M
Sam-A Pharm. Co. Ltd company profile
- Company name
- Sam-A Pharm. Co. Ltd
- Ticker
- 009300.KQ
- ISIN
- KR7009300005
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 271
- Fiscal year end
- December
- Address
- SAMA Building, Seoul, South Korea
- Phone
- 82 2 2056 7283
- Website
- samapharm.co.kr
About Sam-A Pharm. Co. Ltd
Sam-A Pharm. Co., Ltd operates as a pharmaceutical company in South Korea. The company offers a range of pharmaceutical products in the areas of respiratory, anti-biotics, anti-virals, anti-histamines, anti-fungals, dermatology, pain/inflammation, gastrointestinal, cardiovascular, metabolism, urological, and steroids, as well as psychotropic agents; and OTC products in the areas of respiratory, ant-analgesics, gastro-intestinal, topical, oral, and anti-histamines. It also provides NOMA MEGAFFECT for stress relief, eye care, memory and blood lipid concentration enhancement, endurance enhancement, and the supply of vitamins and minerals; and NOMA-F gummy, NOMA CHEWABLE tablet, and NOMA GOLD chewable tablet for growth promotion, enhancement of nutritional deficiency, and supply of vitamins. Sam-A Pharm. Co., Ltd was founded in 1945 and is based in Seoul, South Korea.
Sam-A Pharm. Co. Ltd management
5- Heo JunChief Exec. Officer · born 1971
- Hyeon-Wu LeeManaging Director · born 1960
- Shin-Jun KangManaging Director · born 1965
- Kuk-Hwan ChoiManaging Director · born 1964
- Hyeong-Cheol NamManaging Director · born 1960